Eli Lilly (LLY)

Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?

VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.

Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Viking and Roche both reported positive results for their weight-loss drugs Tuesday.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

The top healthcare stock has been underperforming the market, and its returns haven't been as impressive as in recent years.

The unlocking of SpaceX shares is reshaping the communications sector.

It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.

These companies may perform well in any market environment.

The global AI training dataset market was valued at USD 3.2 billion in 2025 and is projected to reach USD 16.3 billion by 2033, expanding from USD 3.9 bill

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Ch...

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.

FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.

Ahead of Q4 2026, analysts favor Western Digital, NVIDIA, Vertiv, Eli Lilly, and JPMorgan Chase as steady, best-in-class stocks offering growth with less volatility for buy-and-hold investors.

The company is still looking to bounce back after the beating it took in recent years.

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

The drugmaker has a lot riding on continued clinical progress.

Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.

These stocks have been struggling lately, but they could be underrated buys in the long run.

Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company’s executive vice president and president of Lilly USA and G

The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those.

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.